Related Experiment Video
Updated: Mar 23, 2026

06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
28.0K
Progressive diffuse meningioangiomatosis: Response to bevacizumab treatment
Shlomit Yust-Katz1, Gregory Fuller2, Suzana Fichman-Horn2
1From Davidoff Cancer Center (S.Y.-K., D.L., T.S.), Rabin Medical Center (S.F.-H., N.M., E.I., J.L., I.S.), Petah Tikva; Tel-Aviv University (S.Y.-K., D.L., T.S.), Israel; and MD Anderson Cancer Center (G.F.), Houston, TX. liorshlomit@yahoo.com.
Neurology
|April 1, 2016
Abstract
No abstract available in PubMed .
More Related Videos
Related Concept Videos
Treatment Resistent Cancers
1.5K
1.5K
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K

